(MENAFN- GlobeNewsWire - Nasdaq) The hyper-personalized medicine market is experiencing rapid growth due to rising demand for targeted therapies and advances in genomic and AI-driven technologies. Opportunities lie in expanding precision medicine, integrating big data analytics, and developing personalized care platforms, with Asia-Pacific poised for the fastest growth.

Dublin, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The "Hyper-Personalized Medicine Market Report 2025" has been added to ResearchAndMarkets's offering.

The "Hyper-Personalized Medicine Global Market Report 2025" provides essential insights for strategists, marketers, and senior management aiming to assess an evolving market landscape. The report targets the hyper-personalized medicine market, which is witnessing robust expansion. It outlines the prevailing market trends and anticipates the future landscape over the next decade and beyond.

The hyper-personalized medicine market is poised for robust growth, expanding from $2.77 trillion in 2024 to $3.18 trillion in 2025, with a projected surge to $5.49 trillion by 2029, achieving a CAGR of 14.9% initially and 14.6% subsequently. This growth is driven by advances in genomic technologies, heightened demand for targeted therapies, increasing healthcare data usage, and investment boosts in biotechnology.

Precision therapies significantly propel this market expansion. These therapies offer tailored treatments by targeting specific genetic or molecular disease characteristics, resulting in enhanced efficacy and reduced side effects. The U.S. FDA's approval of 16 novel personalized therapies for rare diseases in 2023, compared to 6 in 2022, exemplifies this rising trend.

Renowned industry players include Pfizer Inc., Johnson & Johnson, Roche Holding AG, Bayer AG, Sanofi S.A., AstraZeneca PLC, and others. North America dominated the market in 2024, with Asia-Pacific poised for the fastest growth. Key regions covered include Asia-Pacific, Western and Eastern Europe, North America, South America, the Middle East, and Africa, encompassing countries like the USA, Canada, China, India, and more.

Global trade policies, notably the 2025 U.S. tariff hikes, are impacting the sector by imposing challenges on APIs, glass vials, and lab equipment. Companies are responding by expanding production in India and Europe, stockpiling inventories, and seeking trade exemptions for essential medicines.

The hyper-personalized medicine market encompasses a range of categories, from diagnostics and therapeutics to nutrition, utilizing genomics, AI, and real-time monitoring technologies. The market report provides comprehensive insights into global market size, regional shares, and key trends, delivering a holistic analysis of sustainable strategies in this rapidly evolving industry.

The market thrives on revenues from services like genomic sequencing, AI diagnostics, and the sale of genetic testing kits and wearable health trackers. These revenues reflect goods' factory gate values, emphasizing the service providers' direct sales and related offerings.

This optimistic outlook is tempered by ongoing shifts in international trade relations, necessitating updated forecasts and strategic recommendations. The abrupt tariff increases are impacting production costs and supply chain dynamics, compelling companies to adapt rapidly to sustain growth in this dynamic international arena.

Key Attributes:

Report Attribute	Details
No. of Pages	250
Forecast Period	2025 - 2029
Estimated Market Value (USD) in 2025	$3188.03 Billion
Forecasted Market Value (USD) by 2029	$5490.15 Billion
Compound Annual Growth Rate	14.6%
Regions Covered	Global

Scope:

Markets Covered:

• Product: Diagnostics, Therapeutics, Care, Nutrition and Wellness
• Technology: Genomics, Proteomics, Bioinformatics, Metabolomics
• Application: Oncology, Neurology, Blood Safety, Diabetes, Autoimmune Diseases, Cardiology
• End User: Hospitals, Diagnostic Centers, Research Institutes

Subsegments:

• Diagnostics: Genomic Sequencing, Biomarker Testing, Molecular Diagnostics
• Therapeutics: Targeted Drug Therapies, Gene and Cell Therapy, RNA-based Therapeutics
• Medical Care: Telemedicine, Personalized Treatment, AI Clinical Support, Precision Surgery
• Nutrition and Wellness: Nutrigenomics, Personalized Diets, Microbiome Analysis

Companies Featured

• Pfizer Inc.
• Johnson & Johnson
• Roche Holding AG
• Bayer AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Abbott Laboratories
• Novartis AG
• Danaher Corporation
• Amgen Inc.
• Merck KGaA
• GE Healthcare Technologies Inc.
• Biogen Inc.
• Illumina Inc.
• Guardant Health Inc.
• Berry Genomics Co. Ltd.
• Sophia Genetics SA
• Mapmygenome
• InnoCare Pharma.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Hyper-Personalized Medicine Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN04112025004107003653ID1110293804